Publications by authors named "I B Rasmussen"
Article Synopsis
- Patient-reported outcome measures (PROMs) that assess health-related quality of life (HRQOL) are increasingly important in renal cell cancer (RCC) clinical trials for drug approval and policy making.
- The review identified 48 studies, mostly randomized controlled trials, that utilized 27 different PROMs, but only a small fraction were specifically designed for kidney cancer patients; 46% didn’t use any RCC-specific PROMs at all.
- The most commonly used PROMs focused on issues like pain, fatigue, and sleep quality, highlighting a lack of consistency in the tools used, which complicates the comparison of findings across studies.
In patients previously hospitalised for COVID-19, a 12-week high-intensity interval training (HIIT) intervention has previously been shown to increase left ventricular mass (LVM) immediately after the intervention. In the present study, we examined the effects of the same HIIT scheme on LVM, pulmonary diffusing capacity, symptom severity and functional capacity at 12-month follow-up. In this investigator-blinded, randomised controlled trial, 12 weeks of a supervised HIIT scheme (4 × 4 min, three times a week) was compared to standard care (control) in patients recently discharged from hospital due to COVID-19.
View Article and Find Full Text PDFArticle Synopsis
- The FLOW trial investigated the effects of semaglutide on cardiovascular (CV) events and death in individuals with type 2 diabetes and chronic kidney disease (CKD).
- Results showed that semaglutide lowered the risk of CV death, non-fatal heart attacks, and strokes by 18%, and overall mortality by 20% across various levels of CKD severity.
- The beneficial effects of semaglutide were consistent regardless of kidney function, protein levels in urine, or risk classification.
Article Synopsis
- The OPI•AID project focuses on creating personalized algorithms for managing perioperative pain using opioids by considering factors like demographics and surgical details.
- Five parallel reviews will analyze existing research to understand individual responses to opioid treatments in the perioperative setting.
- The findings will aim to enhance individualized treatment strategies and develop a clinically validated personalized opioid treatment algorithm compared to standard practices.
Background: Neoantigens can serve as targets for T cell-mediated antitumor immunity via personalized neopeptide vaccines. Interim data from our clinical study NCT03715985 showed that the personalized peptide-based neoantigen vaccine EVX-01, formulated in the liposomal adjuvant, CAF09b, was safe and able to elicit EVX-01-specific T cell responses in patients with metastatic melanoma. Here, we present results from the dose-escalation part of the study, evaluating the feasibility, safety, efficacy, and immunogenicity of EVX-01 in addition to anti-PD-1 therapy.
View Article and Find Full Text PDF